TOFACITINIB
tofacitinib 5 mg tablet, 56
TOFACITINIB (11675L)
11675L
Manner of administration:Oral
Restriction
Indication: Severe psoriatic arthritis
Treatment phase: Continuing treatment
Restriction
Indication: Severe psoriatic arthritis
Treatment phase: Continuing treatment - balance of supply
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 56 | # of repeats: 5 | DPMQ: $1,155.38 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Xeljanz | |||||